Document is current
Any future updates will be listed below
-
Authors
Ozog, Stosh https://orcid.org/0000-0002-2120-9140
Krantz, Elizabeth M.
Tindbaek, Karyn
Munoz, Julian
Liu, Winnie L.
Chalal, Clementine
Pernikoff, Sara https://orcid.org/0000-0002-3795-2932
Yahya, Khaleel
Stevens-Ayers, Terry https://orcid.org/0000-0002-7546-8439
Dasgupta, Sayan https://orcid.org/0000-0001-5271-7247
Cowan, Andrew J.
Green, Damian J.
Gauthier, Jordan https://orcid.org/0000-0002-5769-8409
Till, Brian G. https://orcid.org/0000-0002-4718-8288
Gardner, Rebecca A. https://orcid.org/0000-0003-1532-3200
Shadman, Mazyar
Bleakley, Marie https://orcid.org/0000-0002-7018-8702
Boeckh, Michael https://orcid.org/0000-0003-1538-7984
Boonyaratanakornkit, Jim https://orcid.org/0000-0001-5858-2662
Turtle, Cameron J. https://orcid.org/0000-0002-4722-4461
Hill, Joshua A. https://orcid.org/0000-0002-7665-7100
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (5U01CA247548)
U.S. Department of Health & Human Services | National Institutes of Health (T32 CA009351)
- License Information
-
More Information
Article History
Received: 14 July 2025
Accepted: 17 March 2026
First Online: 7 April 2026
Competing interests
: A.J.C. reports advising and consultancy for Sebia, Janssen Pharmaceuticals, BMS, Sanofi, HopeAI, Adaptive Biotechnologies, AbbVie, Kite/Arcellx, and research funding from Janssen Pharmaceuticals, BMS, Juno/Celgene, Sanofi, Regeneron, IGM BIosciences, Nektar, Harpoon, Caelum, Opna Bio, and Karyopharm. D.J.G. reports advising for Juno Therapeutics, Seattle Genetics, Janssen Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline, Ensoma, and Legend Biotech, and research funding from Juno Therapeutics, Seattle Genetics, Janssen Pharmaceuticals, Bristol-Myers Squibb, SpringWorks Therapeutics, Sanofi, AstraZeneca, and Cellectar Biosciences. J.G. reports consultancy for Bristol-Myers Squibbs, Sobi, Legend Biotech, Janssen, Kite Pharma, MorphoSys, and research funding from Sobi, Juno Therapeutics, Celgene, Angiocrine Bioscience, Faron Pharmaceuticals, CARGO Therapeutics, and CytoAgents. B.G.T. reports consultancy for Proteios Technology and research funding from Mustang Bio and BMS/Celgene. R.A.G. reports royalties from BMS related to patents in the CAR-T cell field. C.J.T. reports advising for Caribou Biosciences, T-CURX, Myeloid Therapeutics, ArsenalBio, Cargo Therapeutics, Celgene/BMS Cell Therapy, Differentia Bio, eGlint, IQVIA, research funding from Juno Therapeutics/BMS, Nektar Therapeutics, 10X Genomics, Genscript, Kite/Gilead, Umoja Biopharma, and consultancy for Prescient Therapeutics, Century Therapeutics, Boxer Capital, Novartis, Merck Sharp and Dohme, and AbbVie. J.A.H. reports consultancy for Moderna, Allovir, Gilead, Takeda, CSL Behring, Karius, Geovax, and Sanofi, and research funding from Gilead, Takeda, Merck, Geovax, and Sanofi. All others deny any competing interests.
